"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

And based on the data so far, amycretin looks even more impressive than Wegovy and Eli Lilly's Zepbound, the two top-selling weight loss drugs. In a 72-week study, Zepbound's mean weight loss was ...

Eli Lilly has today forecast annual profit largely above Wall Street estimates, providing some relief to investors after ...